CD83 and endometrial cancer: We hypothesized that the broader array of antibodies used (anti-CD83, -DC-LAMP, -CD1a, -CD1c, -CD123, and -DC-SIGN) would clarify the correlation between DCs’ infiltrates and the clinicopathological features of endometrial cancers.